By Katie Ellis
August 2, 2018
School of Pharmacy and Pharmaceutical Sciences faculty and staff have moved into the school’s new, state-of-the-art, 105,000 sq. ft. building at Binghamton University’s Health Sciences Campus in Johnson City, N.Y.
“This is Binghamton University’s first new professional school in almost a decade,” said Founding Dean Gloria Meredith, “And the University has made a substantial investment to build a quality professional school that will become a leader in interprofessional, patient-centered care and research.”
Constructed with $60 million from New York state, the building will open its doors to the classes of 2021 and 2022 later this month as students begin classes and work with faculty on two floors devoted to a high-quality pharmacy education program and two floors devoted to cutting-edge, contemporary, multidisciplinary research. The research and clinically focused school is training the next generations of Doctor of Pharmacy (PharmD) graduates to deliver evidence-based, patient-centered pharmaceutical care to diverse groups of patients, especially those who are in under-served rural and geriatric communities.
A state-of-the-art simulation lab provides students with the resources to work interprofessionally with a wide variety of health professionals – including students in the Decker School of Nursing, social work students from the College of Community and Public Affairs and medical students from SUNY Upstate Medical University in Syracuse – to develop industry leading clinical skills.
Through a formal research track and a capstone experience, students will work with leading scholars/researchers in pharmacy practice, health outcomes and pharmaceutical science. Research focuses on approaches to testing new drugs to treat human disease, development of sensitive and reliable outcome measures for patients and improvement of clinical decision-making, impacting both the quality and cost of healthcare. Research will also be conducted on clinical trial networks to ensure the safety and efficacy of new drugs and on pharmaceutical products and services with an eye on improving patient outcomes.
